TY - JOUR
T1 - Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain
AU - Krammer, Florian
AU - Palese, Peter
N1 - Funding Information:
Work on broadly protective and universal influenza virus vaccines in the Krammer and Palese laboratories is supported by NIAID grants and contracts (R01 AI117287 and R01 AI128821 to F. K. and U19 AI109946 and HHSN272201400008C to P. P. and F. K.); PATH; and the US Department of Defense. The Bill and Melinda Gates Foundation and GlaxoSmithKline are funding the cHA phase 1/2 trials
Funding Information:
Financial support. Work on broadly protective and universal influenza virus vaccines in the Krammer and Palese laboratories is supported by NIAID grants and contracts (R01 AI117287 and R01 AI128821 to F. K. and U19 AI109946 and HHSN272201400008C to P. P. and F. K.); PATH; and the US Department of Defense. The Bill & Melinda Gates Foundation and GlaxoSmithKline are funding the cHA phase 1/2 trials.
Publisher Copyright:
© 2019 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2019/4/8
Y1 - 2019/4/8
N2 - Due to limitations of current influenza virus vaccines, new vaccines that mediate broad protection and show high efficacy against seasonal and pandemic viruses are urgently needed. The conserved stalk of the viral hemagglutinin has been identified as potential target antigen for this new generation of vaccines. A vaccination strategy based on chimeric hemagglutinin (cHA), which refocuses the immune response toward the stalk domain and the conserved neuraminidase, is currently being tested in clinical trials. Here we discuss how to improve the cHA antigens to generate vaccine candidates that both induce a broad antistalk response and target conserved immunosubdominant epitopes in the head domain of the hemagglutinin. These novel constructs, termed mosaic hemagglutinins, should provide enhanced protection and should be tested in clinical trials to assess their improved potential as universal influenza virus vaccine candidates.
AB - Due to limitations of current influenza virus vaccines, new vaccines that mediate broad protection and show high efficacy against seasonal and pandemic viruses are urgently needed. The conserved stalk of the viral hemagglutinin has been identified as potential target antigen for this new generation of vaccines. A vaccination strategy based on chimeric hemagglutinin (cHA), which refocuses the immune response toward the stalk domain and the conserved neuraminidase, is currently being tested in clinical trials. Here we discuss how to improve the cHA antigens to generate vaccine candidates that both induce a broad antistalk response and target conserved immunosubdominant epitopes in the head domain of the hemagglutinin. These novel constructs, termed mosaic hemagglutinins, should provide enhanced protection and should be tested in clinical trials to assess their improved potential as universal influenza virus vaccine candidates.
KW - Chimeric hemagglutinin
KW - Heterosubtypic immunity
KW - Influenza virus
KW - Mosaic hemagglutinin
KW - Universal influenza virus vaccines
UR - http://www.scopus.com/inward/record.url?scp=85064496397&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiy711
DO - 10.1093/infdis/jiy711
M3 - Article
C2 - 30715353
AN - SCOPUS:85064496397
SN - 0022-1899
VL - 219
SP - S62-S67
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -